Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2209 - Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)


09 Oct 2016


Poster display


André Mansinho


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


A.B. Mansinho, D. Macedo, I.C. Fernandes, A. Quintela, L.A.;. Costa

Author affiliations

  • Medical Oncology, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), 1649-035 - Lisboa/PT


Abstract 2209


The tumor microenvironment and inflammatory response are hallmarks of cancer progression. The NLR emerged as an indicator of the inflammatory state in patients with cancer, and has been negatively correlated with the prognosis of several solid tumors including mCRPC. The NLR is an available and easy to use tool and the authors assessed its role in the prognosis and response duration of patients treated with AA.


Retrospectively evaluated clinical data of patients with mCRPC from a single high volume center, with disease evaluable according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, that underwent at least 12 weeks of AA. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count in the peripheral blood at baseline and at 12 weeks of treatment. NLR was stratified in two groups, > 5 and 


112 patients were treated with AA between 01/01/2013 and 31/12/2015, 90 for at least 12 weeks. The average NLR was 4,35 ± 3,07 (1,15-22,10). 33 had a NLR > 5 (36,7%), with both groups characteristics balanced. Median OS was 16,6 months in the NLR > 5 group and 27,1 months in the NLR  5 at baseline converted to  5 group and 9,7 months in the NLR 


The NLR was prognostic in this analysis, with a NLR > 5 at baseline associated to a worse OS. There was no relation between NLR and response duration, with similar PFS in both groups. There was a trend for better OS in patients with a NLR > 5 at baseline that converted to 

Clinical trial identification

Legal entity responsible for the study

Centro Hospitalar Lisboa Norte, Hospital de Santa Maria


Serviço de Oncologia Médica, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings